Idorsia Competitors and Similar CompaniesClear all
Novartis's competitors and similar companies include Pfizer, Roche, Regeneron Pharmaceuticals, Vifor Pharma, Roivant Sciences and Biocon.
 Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Roche Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  Vifor Pharma Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products. | |||
Founding Date | Founding Date 1996 | Founding Date 1849 | Founding Date 1896 | Founding Date 1988 | Founding Date 1927 | Founding Date 2014 | Founding Date 1978 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Glattbrugg, CH HQ Buenos Aires, AR Melbourne, AU Melbourne, AU Wien, AT Antwerpen, BE São Paulo, BR see more | Locations London, GB HQ Basel, CH Boston, US New York, US | Locations Bengaluru, IN HQ Bengaluru, IN Hyderabad, IN Visakhapatnam, IN Dublin, IE Kuala Lumpur, MY Puchong, MY see more | |
Employees | Employees 75,883 | Employees 88,0006% increase | Employees 103,249 | Employees 15,1068% increase | Employees 2,200 | Employees 908 | Employees 16,315 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) N/A | Valuation ($) 102.2 b | Valuation ($) N/A | Valuation ($) 8.8 b | Valuation ($) N/A |
Financial | |||||||
Revenue (est.) | Revenue (est.) $51.7b (FY, 2024) | Revenue (est.) $63.6b (FY, 2024) | Revenue (est.) CHF60.5b (FY, 2024) | Revenue (est.) $14.2b (FY, 2024) | Revenue (est.) CHF1.8b (FY, 2021) | Revenue (est.) $124.8m (FY, 2023) | Revenue (est.) ₹142b (FY, 2024) |
Cost of goods | Cost of goods $7.7b (FY, 2024) | Cost of goods $17.9b (FY, 2024) | Cost of goods CHF12.1b (FY, 2024) | Cost of goods $2b (FY, 2024) | Cost of goods CHF498.7m (FY, 2021) | Cost of goods N/A | Cost of goods ₹50.9b (FY, 2024) |
Gross profit | Gross profit $45.2b (FY, 2024) | Gross profit $45.8b (FY, 2024) | Gross profit CHF50.3b (FY, 2024) | Gross profit $12.2b (FY, 2024) | Gross profit CHF1.3b (FY, 2021) | Gross profit N/A | Gross profit ₹101.9b (FY, 2024) |
Net income | Net income $11.9b (FY, 2024) | Net income $8.1b (FY, 2024) | Net income CHF9.2b (FY, 2024) | Net income $4.4b (FY, 2024) | Net income CHF265.4m (FY, 2021) | Net income $4.2b (FY, 2023) | Net income ₹13b (FY, 2024) |
Operating ⚠ | |||||||
Patients | Patients 10 m (FY, 2022) | Patients N/A | Patients 22.8 m (FY, 2023) | Patients N/A | Patients N/A | Patients N/A | Patients N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 4 (Q2, 2021) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 25 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (Q2, 2021) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 27 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (Q2, 2021) | Phase III Trials Products N/A |
Registration Phase Products | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 10 (FY, 2021) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 1 (Q2, 2021) | Registration Phase Products N/A |
Funding | |||||||
Total funding raised | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 7.8b | Total funding raised $ 53.9m | Total funding raised N/A | Total funding raised $ 1.9b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Pfizer
HQ
New York, US
Employees
88,000↑ 6% increase
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyRoche
HQ
Basel, CH
Employees
103,249
Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas.
View companyRegeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
15,106↑ 8% increase
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
View companyVifor Pharma
HQ
Glattbrugg, CH
Employees
2,200
Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products.
View company